TARGET SPECIFIC AND DRUG LOADED IRON OXIDE NANOPARTICLES FOR CANCER IMAGING AND
用于癌症成像和靶向治疗的载药氧化铁纳米颗粒
基本信息
- 批准号:7950409
- 负责人:
- 金额:$ 20万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2010-03-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The goal of the proposed study is to develop therapeutic imaging nanoparticles for targeted drug delivery and non-invasive tumor imaging of primary and metastatic breast cancer. We hypothesize that systemic delivery of peptide-conjugated iron oxide nanoparticles targeting to urokinase plasminogen activator receptor (uPAR) leads to selective accumulation and internalization of the iron oxide nanoparticles in breast cancer cells. This allows delivery of therapeutic agents that are encapsulated in the iron oxide nanoparticles into the tumor cells. Enrichment of the iron oxide nanoparticles in tumor cells and tumor environment generates strong magnetic signals for detection of primary and metastatic breast cancer lesions as well as real-time monitoring of therapeutic effects by magnetic resonance imaging. The proposed research will be the first to use multifunctional nanoparticles that selectively target to breast cancer cells and tumor environment, and have the ability to deliver therapeutic agents into the cells. It is well known that high levels of uPAR are present in all stages of breast cancer and are closely associated with aggressive tumor types and poor prognosis. Therefore, the proposed nanoparticles are therapeutic imaging nanoparticles that have great potential for future clinical application in detection and treatment of breast cancer.
这项研究的目的是开发治疗成像纳米颗粒,用于原发性和转移性乳腺癌的靶向药物递送和非侵入性肿瘤成像。我们假设,全身递送靶向尿激酶纤溶酶原激活物受体(uPAR)的肽缀合的氧化铁纳米颗粒导致氧化铁纳米颗粒在乳腺癌细胞中的选择性积累和内化。这允许将包封在氧化铁纳米颗粒中的治疗剂递送到肿瘤细胞中。氧化铁纳米颗粒在肿瘤细胞和肿瘤环境中的富集产生强磁信号,用于检测原发性和转移性乳腺癌病变以及通过磁共振成像实时监测治疗效果。这项研究将首次使用多功能纳米颗粒,选择性地靶向乳腺癌细胞和肿瘤环境,并有能力将治疗剂输送到细胞中。众所周知,高水平的uPAR存在于乳腺癌的所有阶段,并且与侵袭性肿瘤类型和不良预后密切相关。因此,所提出的纳米颗粒是治疗成像纳米颗粒,在未来的临床应用中具有很大的潜力,在乳腺癌的检测和治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW WANG其他文献
ANDREW WANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW WANG', 18)}}的其他基金
OTHER FUNCTIONS "TARGET SPECIFIC AND DRUG LOADED IRON OXIDE NANOPARTICLES FOR CA
其他功能“针对CA的特定目标和载药氧化铁纳米颗粒
- 批准号:
8564318 - 财政年份:2012
- 资助金额:
$ 20万 - 项目类别:
相似国自然基金
花胶鱼类物种Species-specific PCR和Multiplex PCR鉴定体系研究
- 批准号:31902373
- 批准年份:2019
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
DDS type peptide drug discovery and diagnostics development research which makes the target malignant tumor-specific molecules.
DDS型肽药物发现和诊断开发研究,使靶向恶性肿瘤特异性分子。
- 批准号:
19H03438 - 财政年份:2019
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Application of an in vitro cell-based system to investigate the killing of target tissue by drug-specific T-cells
应用体外细胞系统研究药物特异性 T 细胞对靶组织的杀伤作用
- 批准号:
1961494 - 财政年份:2017
- 资助金额:
$ 20万 - 项目类别:
Studentship
EPHX2 phosphatase as a novel target of drug discovery: searches for a physiologically relevant substrate and a specific inhibitor
EPHX2磷酸酶作为药物发现的新靶点:寻找生理相关底物和特异性抑制剂
- 批准号:
17H02201 - 财政年份:2017
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of specific molecular target therapy for oral cancer using new drug delivery system
利用新型给药系统开发口腔癌特异性分子靶向治疗
- 批准号:
16K11698 - 财政年份:2016
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of the specific molecular target drug for oral cancer
口腔癌特异性分子靶向药物的开发
- 批准号:
25463098 - 财政年份:2013
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of novel molecular target drug for activated Ras protein by the specific protein degradation system
利用特异性蛋白降解系统开发活化Ras蛋白的新型分子靶向药物
- 批准号:
25860095 - 财政年份:2013
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
OTHER FUNCTIONS "TARGET SPECIFIC AND DRUG LOADED IRON OXIDE NANOPARTICLES FOR CA
其他功能“针对CA的特定目标和载药氧化铁纳米颗粒
- 批准号:
8564318 - 财政年份:2012
- 资助金额:
$ 20万 - 项目类别:
Lipid and Carbohydrate Based Systems to Target and Deliver Peptide Drug Candidates to Specific Cells
基于脂质和碳水化合物的系统将候选肽药物靶向并递送至特定细胞
- 批准号:
DP1092829 - 财政年份:2010
- 资助金额:
$ 20万 - 项目类别:
Discovery Projects
Identification of Small Molecule Effectors that target the Fungal-Specific Kinase Drk1 as Novel Antifungal Drug Leads
鉴定靶向真菌特异性激酶 Drk1 作为新型抗真菌药物先导物的小分子效应器
- 批准号:
9205652 - 财政年份:
- 资助金额:
$ 20万 - 项目类别:
Ubiquitin Specific Protease 46 (USP46) as novel drug target in neurodegenerative disease
泛素特异性蛋白酶 46 (USP46) 作为神经退行性疾病的新药物靶点
- 批准号:
9205630 - 财政年份:
- 资助金额:
$ 20万 - 项目类别: